ASCO 2017: Updates on HER2-Positive Breast Cancer Treatment
This video highlights the latest studies presented at the 2017 ASCO Annual Meeting on the treatment of HER2-positive breast cancer.
In this video, Karen Gelmon, MD, of the British Columbia Cancer Agency in Canada, highlights the latest studies on the treatment of HER2-positive breast cancer presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
Gelmon chaired an education session at the meeting on the optimal management of early and advanced HER2-positive breast cancer.
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
![Radiotherapy is a very evidence-based subject. We can tell quite accurately how well we think [a patient] is going to do.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Feecaffda6ab0cbb4f4463586ace2f199eeefa8bf-400x401.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Radiotherapy is a very evidence-based subject. We can tell quite accurately how well we think [a patient] is going to do.")
